ArticleNeoplasia (New York, N.Y.)2016
Mirvetuximab Soravtansine (IMGN853), a Folate Receptor Alpha-Targeting Antibody-Drug Conjugate, Potentiates the Activity of Standard of Care Therapeutics in Ovarian Cancer Models.
Jose F Ponte et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
61 papers cite itlatest 60 shown
this papercites it